International Variability in the Reimbursement of Cancer Drugs by Publically Funded Drug Programs
Open Access
- 1 June 2012
- journal article
- Published by MDPI AG in Current Oncology
- Vol. 19 (3), 165-176
- https://doi.org/10.3747/co.19.946
Abstract
Purpose: Evaluate inter-country variability in the reimbursement of publically funded cancer drugs, and identify factors such as cost containment measures that may contribute to variability. Methods: As of February 28, 2010, licensed indications for 10 cancer drugs (bevacizumab, bortezomib, cetuximab, erlotinib, imatinib, pemetrexed, rituximab, sorafenib, sunitinib, and trastuzumab) were obtained from the drug registries of 6 licensing authorities corresponding to 13 countries or regions: Australia, Canada (Ontario), England, Finland, France, Italy, Germany, Japan, New Zealand, the Netherlands, Scotland, Sweden, and the United States (Medicare Parts B and D). Number of licensed indications reimbursed by public payers and the use of cost containment measures were obtained by survey of health authorities involved in reimbursement and through public documents. Results: The 48 identified licensed indications varied between agencies (range: 36–44 indications). Finland, France, Germany, Sweden, and the United States reimbursed the highest percentage of indications (range: 90%–100%). Canada (54%), Australia (46%), Scotland (40%), England (38%), and New Zealand (25%) reimbursed the least. All 5 countries with the lowest rate of reimbursement incorporated a cost-effectiveness analysis into reimbursement decisions and rejected submissions for reimbursement mainly because of lack of cost effectiveness; in New Zealand, lack of cost effectiveness was the second leading cause of rejection after excessive cost. In 9 countries, risk-sharing agreements were used to contain costs. Indications initially not recommended for reimbursement (9 in Australia, 5 in Canada, and 3 in England, New Zealand, and Scotland) were subsequently approved with risk-sharing agreements or special pricing arrangements. Conclusions: Reimbursement of publically funded cancer drugs varies globally. The cause is multifactorial.Keywords
This publication has 20 references indexed in Scilit:
- Development and economic trends in cancer therapeutic drugs in the UK from 1955 to 2009Journal of Oncology Pharmacy Practice, 2010
- Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payersBMC Health Services Research, 2010
- Ongoing pharmaceutical reforms in FranceApplied Health Economics and Health Policy, 2010
- Limits on Medicare's Ability to Control Rising Spending on Cancer DrugsThe New England Journal of Medicine, 2009
- Characteristics of and trends in the late-stage biopharmaceutical pipeline.2008
- Paying for modern cancer care—a global perspectiveThe Lancet Oncology, 2007
- Reimbursement for Cancer Treatment: Coverage of Off-Label Drug IndicationsJournal of Clinical Oncology, 2006
- Centralized Drug Review Processes In Australia, Canada, New Zealand, And The United KingdomHealth Affairs, 2006
- NSAID-induced bronchospasm--a common and serious problem. A report from MEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority.1999
- Emerging standardization in pharmacoeconomicsClinical Therapeutics, 1998